Articles tagged with Cell Therapies
Researchers identify optimal T cell selection and preparation strategies for adoptive immunotherapy approaches to treat tumors. Naive and early effector T cells are more effective than differentiated T cells in causing regression of large, established melanomas.
Researchers at UCSD found that statins and cholesterol depletors can reduce intracellular calcium levels and inhibit cell growth in pulmonary artery smooth muscle cells, which contributes to idiopathic pulmonary hypertension. This novel mechanism may provide a new approach for treating IPAH with current and future therapies.
New data from the largest study on CML patients (1106) showed improved rates of progression-free survival and durable responses to imatinib. Patients with early cytogenetic responses achieved higher progression-free survival rates, with 93% at 42 months compared to 74% without
Researchers found that adherence to St-Gallen guidelines improved overall survival at 7 years, especially for those at moderate risk of recurrence. Women whose treatment conformed to guideline recommendations experienced better survival and lower recurrence rates compared to those with non-guideline therapy.
Researchers developed a new technique to selectively delete C-fiber neurons, which transmit chronic pain signals, using the drug resiniferatoxin. In animal studies, this approach reduced pain and improved behavior without side effects.
The Russell Berrie Foundation gift will support cellular therapy research at Columbia University Irving Medical Center, aiming to restore body tissues and cure or ameliorate diabetes. The program seeks to engineer cells to produce insulin, potentially sparing patients from daily injections and devastating complications.
Researchers demonstrate that Ebola and Marburg viruses rely on lipid rafts in the cell membrane to gain entry and assemble. This finding opens up potential therapeutic avenues against these deadly pathogens.
Scientists at Uppsala University have identified a gene that regulates mast cell survival upon allergic activation, providing hope for a novel therapy to treat allergies. Inhibition of this gene, A1, leads to the death of mast cells, decreasing their numbers and alleviating allergic symptoms.
Researchers develop new therapies targeting related virus proteins, aiming to neutralize the effects of smallpox. The US population is highly susceptible due to low vaccination rates and limited vaccine stockpiles.
Researchers found that up to 96% of Parkinson's patients experience serious sleep disturbances, often overlooked by doctors. A new study suggests that cabergoline, a long-acting dopamine agonist, offers significant benefits in improving symptoms of sleep disturbance and daytime sleepiness.
A new radiation treatment technique targets head and neck tumors while sparing salivary glands, enabling patients to function more normally. Patients who received intensity-modulated radiation therapy (IMRT) experienced improved saliva flow and quality of life compared to conventional radiation therapies.
Two MS clinical trials halted due to adverse effects confirm the targeted peptide plays a role in the disease. The studies suggest that lower doses are better than higher doses, and immunological tests can determine how targeted therapies work in patients.
Researchers found that early antiviral treatment primes the immune system to suppress viral levels without drugs, achieving temporary suppression in several months. Five patients remained off treatment for up to 11 months, maintaining low viral levels.
A UF pilot study shows that massage and relaxation techniques can safely and effectively reduce pain, tension, and fatigue in patients with sickle cell anemia. The treatments improved blood flow and reduced muscle tension, providing relief from debilitating episodes of severe pain.
Researchers are developing BioMEMs, implant materials and devices that integrate micro- and nanoscale features to affect cellular function. These therapeutic systems use chip technology, material science, and bioengineering to grow heart cells in culture and protect implanted cells with precision.
Researchers found that even after six months of antiretroviral therapy, a substantial percentage of men with HIV remain infectious. The study suggests that men should continue to practice safe sex and follow medication instructions carefully.
A recent San Francisco study found that antiretroviral treatment continues to significantly improve AIDS patient survival rates, with a 60% reduction in risk of death for those receiving HAART. The study also revealed increased survival benefits over time, particularly among those diagnosed between 1996 and 1997.
Two studies compare the efficacy and adherence of the triple nucleoside regimen of Ziagen/Combivir versus PI-containing regimens. Preliminary data show that patients on the Ziagen/Combivir regimen had better viral load suppression, with 68% achieving <400 copies/ml at 24 weeks, compared to 57% on the PI-containing regimen.
Researchers found that adding interleukin-2 to highly active antiretroviral therapy improves CD4 cell counts in recently infected patients. After 48 weeks of treatment, the average CD4 cell count increased significantly in the early IL-2 group compared to the deferred group.
A multi-institutional study found that adding interleukin-2 to antiretroviral therapy increases CD4 cell counts and decreases detectable virus levels in HIV-infected patients. The study showed significant improvements in immunologic function, with 67% of patients achieving low viral loads.
Researchers at NIAID explore a new approach to HIV treatment involving cyclic therapy, which may reduce HAART duration and costs. Preliminary findings suggest that patients can maintain minimal viral loads and adequate CD4+ T cells during intermittent therapy.
Researchers found that adding IL-2 to antiretroviral therapy significantly increases CD4+ T-cell counts in HIV-infected patients. The study's results suggest that IL-2 may be used as a means of maintaining quality of life and decreasing AIDS-defining events.
Researchers at Duke University Medical Center have successfully used a heat-sensitive gene to slow down tumor growth in mice by 300-400 times over baseline. The gene therapy, which uses hyperthermia, also boosts the immune system's ability to fight cancer.
Researchers at Johns Hopkins presented Phase I study results for Taxoprexin DHA-paclitaxel, a novel taxane that tolerates high doses with minimal side effects. The drug delivers more therapeutic agent to tumor cells and less to healthy tissues, improving safety and effectiveness.
Researchers developed an intensive treatment combining radiation and chemotherapy to control locally advanced head and neck cancer, achieving complete local control for 92% of patients. The therapy increased long-term survival to 55%, with most side effects resolving after treatment.
A study of 947 HIV-positive individuals found that hospital admission was linked to unemployment (82%) and poor health status (46%). The study also showed that having a physician experienced in HIV/AIDS management was beneficial for avoiding hospital admissions.
The new guidelines take into account the availability of new anti-retroviral drugs and expanded therapy choices. Recommendations include initiating therapy based on viral load and CD4 cell count, choosing individualized regimens, and monitoring treatment response with CD4 and HIV RNA levels.
The new guidelines take into account the availability of new antiretroviral drugs and expanded therapy choices, recommending individualized treatment plans with a focus on convenience and adherence. Most patients with HIV infection can now live fully active lives with carefully monitored therapy and regimen changes.
A study by American Academy of Neurology finds that 'chasing the dragon' heroin use can produce a progressive brain disorder leading to permanent damage and death. Antioxidant therapy shows promise in treating the condition, but its effectiveness is uncertain.
Researchers found that even after highly sensitive tests detected no viable HIV, the virus quickly rebounded to substantial levels when therapy was stopped. The study suggests that eradicating HIV with current therapies is unlikely due to the presence of latent reservoirs that drugs cannot access.
Researchers found that current anti-HIV drug combinations are effective in suppressing the virus, but may not be enough to eradicate it. Studies show that residual infection persists, with some patients still showing signs of viral replication after years of treatment.
Researchers have demonstrated a faster and safer approach to cancer vaccine therapy, producing encouraging results in melanoma patients. The new method involves using circulating white blood cells and moderate doses of IL-12, showing promise for treating advanced melanoma.
A recent clinical trial found that fetal dopamine cell implants improved movement control in younger Parkinson's patients, but had no significant impact on older patients or daily activities. PET brain scans revealed increased dopamine activity in those who received the implants, but also showed more severe adverse experiences.
Ohio University researchers are producing precise measurements of neutron direction and speed to develop a new cancer treatment. This technology could lead to fewer side effects and more effective treatment options for patients.
A USC-led study shows that photopheresis reduces the number of serious organ rejections in heart transplant patients, potentially allowing for a more targeted therapy. The treatment also appears to have an anti-viral effect, reducing levels of cytomegalovirus (CMV) in the bloodstream.
Clinical trials show substantial increase in leukemia-free survival among AML patients treated with Maxamine Therapy. The treatment has been shown to prevent relapse and prolong remission while maintaining a good quality of life.
Researchers at Chiron Corporation have identified a protein molecule (CD81) that binds to the hepatitis C virus (HCV), providing clues on how the virus infects human cells. This discovery has significant implications for the development of new vaccines and therapeutics to prevent and treat chronic HCV infection.
A study led by Ohio State University found that high-dose cytarabine increased the cure rate of acute myeloid leukemia (AML) patients with core binding factor AML to nearly five times, with a 78% remission rate among those receiving the treatment. The standard dose resulted in only 16% remission rates
A study suggests that triple-drug treatment regimens are superior to less intensive therapies in maintaining HIV suppression. Researchers found that patients who switched from three-drug to two- or one-drug treatment regimens were more likely to experience a resurgence in their HIV levels.
The study aims to scientifically evaluate the benefits of a Chinese herbal formula in alleviating multiple side effects of chemotherapy in early-stage breast cancer patients. Participants will receive either the herbal formula or a placebo, with their progress monitored over 180 days.
Jay A. Levy, a UCSF professor of medicine, suggests delaying antiviral therapy for HIV infection until the CD-4 cell count falls below 400 and the viral load is above 30,000 copies per milliliter. This approach aims to avoid drug resistance and allow the immune system to recover and control the virus.
Researchers at Thomas Jefferson University used antisense therapy to prevent Burkitt's lymphoma development in laboratory mice, delaying tumor onset and decreasing its size. The strategy may also work in human patients who have relapsed after chemotherapy, with potential applications against various types of cancer.
Researchers found that HIV establishes a pool of latently infected immune system cells even with early treatment. These cells can persist for years, posing an obstacle to ultimate control and eradication of the virus. The study suggests that these reservoirs are established very early in infection.
In a Phase II study combining ONYX-015 with standard chemotherapy, nine out of ten patients experienced tumor regressions greater than 50 percent, including two complete responses. Thirty percent of patients treated with ONYX-015 alone showed significant tumor regression.
A small-scale study suggests that hyperbaric oxygen therapy can hasten recovery from stroke and save millions of dollars annually in healthcare costs. The treatment, which combines hyperbaric oxygen with diagnostic testing, may give patients an extra hour to receive treatment, potentially extending the window for intervention.
A nationwide study found a significant decline in HIV-related deaths and opportunistic infections from 1994 to mid-1997, largely due to the use of combination antiretroviral therapy including protease inhibitors. Prescription rates for combination therapy increased dramatically during this period.
A study found that HIV remains in a dormant state within CD4+ lymphocytes even after treatment with triple-drug cocktail therapy. This persistence suggests individuals must continue multiple-drug therapy to prevent reactivation of the infection.
Researchers successfully used gene therapy to grow new blood vessels in eight people with obstructed leg circulation due to atherosclerosis. The therapy, called therapeutic angiogenesis, helped improve blood flow, reduce pain and gangrene risk, and even prevented amputations.
Researchers at Duke University have developed a genetically engineered enzyme treatment to address Pompe disease, a condition causing skeletal, heart, and lung muscle destruction. The new therapy will be tested in infants with the most severe symptoms first.
Scientists at Case Western Reserve University have created artificial human chromosomes, offering a powerful tool for studying human genetics and potentially treating genetic diseases. The synthetic microchromosomes demonstrate normal centromeric activity, genetic stability, and continued gene expression.
Researchers found that self-administered IL-2 injections can produce significant increases in CD4+ T cells in HIV-infected patients. Those with higher initial CD4+ T cell counts had the best responses, with almost half sustaining increases of at least 200 cells/mm³ after one year.
A Duke University study found that patients who received magnesium during CPR were 69% less likely to experience brain damage and had better neurological outcomes. The researchers discovered that magnesium may have neuroprotective effects by preventing calcium flow into brain cells, but more trials are needed to confirm the results.
Preliminary results from ACTG 315 show that an antiretroviral drug cocktail can partially restore immune function in people with moderately advanced HIV disease. The study found increases in CD4+ T cell counts, decreased plasma levels of HIV, and improved immune response.
A study published in Science journal demonstrates the efficacy of vascular targeting agents (VTAs) in treating large solid tumors. VTAs selectively occlude tumor vasculature, causing massive tumor cell death and advanced necrosis within 72 hours. The treatment is well-tolerated and results in complete or partial tumor regressions in mice.
The University of Maryland Medical Center now offers a new therapy to prevent stroke disability using the FDA-approved drug Activase. This clot-busting treatment is administered intravenously and can significantly reduce disability risk for patients who receive it within three hours after symptom onset.